---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-114891"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:39:40.673548+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Soleno Q1 net loss $43.8M; VYKAT XR launch: 268 patient forms, 131 prescribers

## Summary
- VYKAT XR approved by FDA Mar 26; treatments started Apr 14; 268 patient start forms and 131 prescribers through May 6.
- Q1 net loss $43.8M ($0.95 EPS) vs $21.4M ($0.59) a year ago; no revenue yet.
- Cash and marketable securities $290.0M; operating cash use $32.8M in quarter.
- R&D expense $13.5M; SG&A $29.3M, reflecting launch preparation costs.
- MAA submission to EMA for DCCR on track for Q2 2025; contingent consideration liability $17.8M.

## SEC filing metadata
- accession: 0001193125-25-114891
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312525114891/0001193125-25-114891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312525114891/d56501d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-114891
- JSON: https://secwatch.observer/filing/0001193125-25-114891.json
- Plain text: https://secwatch.observer/filing/0001193125-25-114891.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.